Caris Life Sciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
12analysts covering
FY Revenue (est.)
$1Bnext fiscal year
FY EPS (est.)
$0.14next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results Conference Call | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Annually812MTarget: $1.0 billion to $1.02 billion
Clinical Therapy Selection Cases Annually199.3KTarget: Approximately 20% growth year-over-year
Gross Margin Quarterly66.0%Target: Maintain premium pricing and stable reimbursement
Watch Items
- Regulatory approval of Caris Assure Blood-Based Testing by the New York State Department of HealthTrigger: Official authorization or rejection noticeAction: Assess market access expansion and update clinical adoption forecasts
- Clinical validation progress of the Detect multi-cancer early detection (MCED) testTrigger: Publication of final clinical trial data or FDA submission milestonesAction: Re-evaluate long-term revenue growth projections and addressable market expansion
Research as of 19 Jun 2026